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The Responsibility of Research Universities to Promote
Access to Essential Medicines
Ellen F.M. 't Hoen, LL.M.*
INTRODUCTION
One-third of the world's population lacks access to essential medicines.
In the poorest parts of Africa and Asia, this figure climbs to one-half. This
global health and medicines crisis is the result of increased microbial
resistance to older medicines, discontinued production of unprofitable
existing medicines, and the prohibitive price of many drugs. In addition,
very few new drugs are being developed to tackle major diseases affecting
people in poor countries. Many other factors also contribute to the
problem of limited access to essential medicines, including logistical supply
and storage problems, substandard drug quality, and the inappropriate
selection and use of drugs.
This piece focuses on the role universities can play in helping to
improve access to medicines in developing countries. Most basic medical
research in the United States takes place at universities. Universities can
take steps to increase the amount of research relevant to health in the
developing world. Universities also hold patents on many important
medicines. By managing this intellectual property (IP) responsibly,
universities can do much to ensure access to medical innovations in
developing countries.
SUSTAINABLE ACCESS TO MEDICINES: A LONG WAY OFF
Infectious diseases kill over ten million people each year, with the
majority of these deaths occurring in the developing world. The leading
causes of illness and death in Africa, Asia, and South America-regions
* Ellen 't Hoen is the Policy Advocacy and Research Coordinator of the Campaign for
Access to Essential Medicines of M6decins Sans Fronti~res.
1. Bernard Pcoul et al., Access to Essential Drugs in Poor Countries: A Lost Battle?, 281
JAMA 361- 67 (1999).
2. WHO, THE WORLD HEALTH REPORT 2002, at 186-87 (2002).
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that account for four-fifths of the world's population-are HIV/AIDS,
respiratory infections, malaria, and tuberculosis.
In particular, the magnitude of the AIDS crisis has drawn attention to
the fact that millions of people in the developing world do not have access
to the medicines that are needed to treat disease or alleviate suffering.
Each day, nearly eight thousand people die of AIDS in the developing
world). One key factor preventing access to medicines in poor countries is
the high price of new drugs. Prohibitive drug prices are often the result of
IP protection, which usually takes the form of a patent. The owners of IP
have a responsibility to consider measures to ensure that IP does not
become an unacceptable barrier to appropriate health care in developing
countries.
The high price of antiretrovirals-the class of drugs prescribed to treat
HIV/AIDS-prevents many in developing countries from using these
drugs. While in recent years, some pharmaceutical companies have
responded to growing public pressure to lower the prices of certain AIDS
medicines for developing countries, their efforts have been neither
systematic nor sufficient. For example, until January 2003, more than three
years after the need for access to medicines made world headlines at the
World Trade Organization's (WTO) Seattle conference, one
pharmaceutical company was charging $2,000 a year more in Guatemala
than in Switzerland for its AIDS drug. Only after months of public pressure
did the price of the drug come down in Guatemala.t
The pharmaceutical industry usually justifies high prices for medicines
by pointing to the high costs of drug research and development (R&D).
But many antiretroviral medicines were initially developed by public
research institutes-including universities-and not by pharmaceutical
companies. Public research institutes have heavily contributed to the
development of many of the most important AIDS drugs, including
zidovudine, stavudine, zalcitabine, abacavir, and a number of protease
inhibitors.'
Stakudine (also known as d4T) is an important nucleoside reverse
3. UNAIDS, REPORT ON THE GLOBAL HLV/AIDS EPIDEMIC, at 125, 129, 133 (2000),
http://www.unaids.org/epidemnic-update/report/Epi-report.pdf (Mar. 24, 2002). This
document outlines the statistics utilized to reach the generally recognized figure of eight
thousand deaths per day due to AIDS in the developing world.
4. Associated Press, Roche Cuts Price of AIDS Drug to Nations (Feb. 13, 2003), available at
http://ww.aegis.com/news/ap/2003/AP030220.html (last isited May 14, 2003).
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transcriptase inhibitor used in antiretroviral combination therapy to treat
HIV/AIDS. Stavudine was developed by researchers at Yale University,
which holds the patent on the drug. Yale licensed the stavudine patent to
Bristol-Myers Squibb (BMS), which currently sells stavudine under the
brand name Zerit. Zerit has been a great commercial success for both BMS
and Yale. In 2000 Yale earned over $40 million in royalties from the
stavudine license.
In March 2001, researchers and students campaigned on the Yale
campus, demanding that Yale not enforce its stavudine patent in South
Africa so that generic versions of the drug could be used. In South Africa
at that time, the price of the generic version of stavudine was thirty-four
times less than the price of BMS' brand name Zerit. Yale professor Dr.
William Prusoff, who, with the late Dr. Tai-Shun Lin, demonstrated the
value of stavudine in treating AIDS, stated publicly, "People shouldn't die
for economic reasons, because they can't afford the drug."'
Under pressure from researchers, students, and access advocates, Yale
renegotiated its license with BMS to ensure the availability of generic
versions of stavudine (d4T) in developing countries. 8 This action showed
that research institutions like Yale can play a central role in improving
access to their innovations. In light of this power, it is imperative that
universities and other research institutions be aware of the global
implications of their patent and licensing policies.
DRUG ACCESS AND R&D: TWO SIDES OF THE SAME COIN
Developing countries account for four-fifths of the world's population,
but less than ten percent of the global pharmaceutical market. Because the
development of medicines is almost entirely profit-driven, investment in
R&D related to the health needs of people in developing countries has
come to a near standstill."
6. YALE UNIXT 1SnY OFFICE OF COOPERATIVE RESEARCH, 1999-2000 ANNUAL RFPORI
(2000), http://www.yale.edu/ocr/images/docs/ocrreport_99-OO.pdf (last visited July 16,
2003).
7. Philippe Demenet, The High Cost of Living: Yale Shares Profits from AIDS Drugs,
Le Monde Diplomatique, Feb. 2002, http://iiondediplo.com/2002/02/04stavudine (last
visited May 13, 2003). For further details see the Consumer Project on Technology page on
stavudine at http://w%-w.cptech.org/ip/health/d4T.html.
8. Julian Borger & Sarah Boseley, Campus Revolt Challenges Yale over $40m AIDS Lrug,
THE GUARDkN (Manchester, U.K), Mar. 13, 2001.
9. Patrice Trouiller et al., Drug Developmeat brNeglected Diseases: A Deficient Market and
a Public-Health Polio ; Failure, 359 THE LANCET 2188 (2002).
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As a result, many of the diseases common in the developing world
remain difficult to treat, while others are completely untreatable. For
example, there is a growing need for new medicines to combat resistant
strains of malaria and tuberculosis, to replace the ineffective and toxic
drugs for sleeping sickness and Chagas disease. and to find treatments for
diseases like dengue fever and Buruli ulcer that are currently almost
untreatable.
The rationale of the patent system is to stimulate R&D by offering a
temporary monopoly in exchange for beneficial innovation. Medical
research aims to contribute to the advancement of human health, but in
reality, it is primarily people in wealthy countries who benefit from medical
progress. Ninety-seven percent of the patents held worldwide are in the
hands of individuals and companies in industrialized countries, and eighty
percent of the patents granted in developing countries belong to residents
of industrial countries.'
World Bank estimates suggest that developing countries will be the net
losers in an increasingly global patent system." The implementation of the
WTO Agreement on Trade Related Aspects of Intellectual Property Rights
is expected to further inflate drug prices, while increased R&D investment,
despite higher levels of IP protection, is not expected.'2 Certainly, strict IP
laws are unlikely to stimulate investment in non-profitable areas such as
tropical diseases.
Market forces will not solve the access and R&D crisis. Therefore, the
public sector, including universities and public research institutes, must
step in where the market fails. The activities of the public sector should be
guided by global health needs, and IP should be managed with the intent
of increasing access to medicines and stimulating further research.
MARKET PROSPECTS Do NOT EQUAL HEALTH NEEDS
Investments in health-related R&D tends to gravitate towards illnesses
10. U. N. DEVELOPMENT PROGRAMME, HUMAN DEVELOPMENT REPORT 68 (1999), available
at http://hdr.undp.org/reports/global/1999/en/ (last visited May 13, 2003).
11. COMMISSION ON INTELLECTUAL PROPERTY RIGHTs, INTEGRATING INTELLECTUAL
PROPER y RIGirrs AND DEVELOPMENT POLiCY 21 (2002), available at
http://www.iprcommission.org/graphic/documents/finalreport.htm (last visited May 13,
2003).
12. Access to Essential Medicines Campaign and the Drugs for Neglected Diseases
Working Group, M6decins Sans Frontibres, Fatal Imbalance: The Crisis in Research and
Development for Drugs for Neglected Diseases 10-18 (2001), available at
http://www.msfiorg/source/access/2001/fatal/fatal.pdf (last visited Mar. 24, 2002).
111:2 (2003)
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or symptoms that offer the greatest potential return on investment,
regardless of actual health needs. When it comes to priority-setting for
R&D in the health field, money talks louder than needs. Pharmaceutical
innovation does not necessarily equal therapeutic innovation. An
assessment of 2,257 new products that were brought to the health market
in France between 1981 and 2000 shows that sixty-three percent of new
products were "me-too" drugs (those that offer no therapeutic gain over
existing drugs). Only seven products (0.13%) represented real therapeutic
breakthroughs." In the United States, less than five percent of the drugs
introduced by the top twenty-five pharmaceutical companies were
therapeutic advances. Of these, seventy percent were developed with
government involvement. 4 While sixty-eight percent of the 1,393 new
chemical entities registered world wide for marketing over the last twenty-
five years were classified as "me-too" drugs, only one percent were for
tropical diseases and tuberculosis, diseases that together account for over
eleven percent of the worldwide disease burden.'
Almost all R&D activities are currently undertaken in the
industrialized world. Ensuring R&D for neglected diseases in the
developing world will require a strong commitment by all actors involved,
including research institutions and universities in wealthy countries.
However, academic research is increasingly guided towards avenues
that may yield profitable returns. Moreover, those activities that do result
in progress in the field of neglected disease are often not taken up by the
private sector and translated into products useful to patients in developing
countries. This is shown most strikingly in the cases of sleeping sickness
and leishmaniasis. These parasitic diseases cause significant illness and
death in the developing world and urgent health tools are needed.
Scientists have long studied these parasites and know a great deal about
their molecular biology, immunology, and genetics. Yet, despite an urgent
need for new medical tools, many pharmaceutical companies are not
working to develop new diagnostics, medicines, or vaccines for these
diseases. 16
A PUBLIC RESPONSIBILiTY BEYOND BORDERS: THE ROLE OF UNIVERSITIES
A Yale initiative to bring together a group of experts in public health,
13. A Look Back at 2000, 10 PREscRiRE INTERNATiONAl 52, 52-54 (2001).
14. U. N. DEVELOPMENT PROGRAMME, supra note 9, at 69.
15. Trouiller et al., supra note 8, at 2189.
16 Id. at 2]90.
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IP management, and university policy on September 25, 2002, signaled a
willingness to address the role of universities in promoting access to
essential medicines. The group discussed what universities as IP holders
can do to promote access to essential medicines and medical technologies
in developing countries. The report from that meeting identified the
crucial role that universities can play in the development of new medicines
and medical technologies, stressing the need to create and implement best
practices in this area. 7
The decisions universities make when patenting and licensing their
technologies can help determine whether individuals in developing
countries have access to the end products of university research. University
research is "upstream" in the development process, meaning that
universities have potential early leverage, though they rarely know in
advance whether or not a product will result in a marketable technology
useful in developing countries. This suggests the importance of
establishing a policy framework upfront and then ensuring its consistent
application.
Those attending the Yale meeting generally agreed upon the following
principles to guide universities in establishing a framework for making
patenting and licensing decisions:
" University research is intended to advance the common public
good, a primary element of which is the advancement of health;
* Global public health concerns need to be an important part of
patenting and licensing decisions;
* The success of patenting and licensing programs should be
measured according to their impact upon public health;
* University IP policies should be implemented in a manner
supportive of developing countries' rights to protect public health
and, in particular, to promote access to medicines for all; and
* Technology transfer to develop capacity in developing countries is
an important part of universities' mandate to advance knowledge
and the social good.
Universities should consider different strategies to implement these
principles, including not patenting or allowing their licensees to patent in
developing countries, and issuing non-exclusive licenses for developing
country markets.
17. Yale Ctr. for Interdisciplinary Research on AIDS, Access to Essential Medicines and
University Research: Building Best Practices (2002),
http://cira.med.yale.edu/whats-new/Essential%20meds,%20final%20report.doc (last
visited July 16, 2003).
111:2 (2003)
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Universities must also be aware of the effect that an IP strategy will
have on innovation. In some cases, exclusive rights to sell a drug in the
developing world may be the only way to encourage research because no
other market exists for the drug. However, because developing country
markets are small and provide limited financial incentive for research,
there is cause to think such cases will be rare.
Changes in university practice will require collective action and
leadership. Participants at the Yale meeting were clear that where
universities act together they can successfully establish norms and
implement best practices. In a recent positive step, an assembly of the
American Medical Students Association (AMSA) adopted a resolution
urging universities to follow the principles discussed at the Yale meeting
when making patenting and licensing decisions that potentially impact
access to essential medicines and medical technologies worldwide.
It is encouraging to see that universities and researchers in wealthy
countries are increasingly aware of global health needs and are working to
ensure that the fruits of medical progress are not withheld from people in
developing countries. Biomedical research in university laboratories
should indeed be guided by policies that take global health needs into
account.
Universities should also review their existing research incentives. For
example, researchers should not be rewarded solely for publication or
patenting, but also for ensuring that innovations actually reach the people
who need access to them. Western universities have an obligation to take a
global perspective and look beyond market opportunities in the United
States and Europe when considering research priorities.
CONCLUSION
The Yale initiative on "Access to Essential Medicines and University
Research: Building Best Practices" deserves follow-up within the public
research sector. The meeting concluded that changes in university practice
will require collective action and leadership and acknowledged that
universities can act together to successfully establish norms and implement
best practices. This enterprise must also take an international dimension.
Increasingly, research activities are becoming global, as are the initiatives
to tackle the R&D divide.
John Barton, Professor of Law at Stanford University and Chair of the
U.K. Commission in Intellectual Property Rights, has proposed a treaty to
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preserve the global scientific and technology commons. 8 He argues that
science and technology require a commons of data, ideas, and insight, and
that all scientists will benefit from having access to the work of their
predecessors. Such a commons should be global. Existing restrictions to
creating a commons-such as licensing regulations that favor nationals
and the global trend to expand the scope of IP protection to include basic
ideas, procedures, methodologies, and research tools-need to be
overcome. This requires an international treaty to create a global scientific
and technology commons. This treaty could include a commitment
ensuring that the benefits of publicly funded research are made available
to all and not just to nationals of a few wealthy countries.
M4decins Sans Frontires (known in the U.S. as Doctors Without
Borders), together with other organizations, is exploring the feasibility of a
new Essential Health Technology R&D Convention to address
international R&D priorities, and to ensure the development of and access
to new essential medicines, vaccines, diagnostics, and equipment. Such a
convention would:
* Define a needs-driven international R&D priority agenda;
* Secure commitments from all countries to contribute to R&D for
health;
* Establish a financing system for sharing the burden of the cost of
this R&D;
* Define appropriate funding and incentive mechanisms for
governments to fulfill their commitments to essential health
technology R&D.
* Establish and strengthen international mechanisms for exchanging
and transferring research results, knowledge, and technology; and
* Ensure that developing countries play a central role in public R&D,
through North-South and South-South collaboration, and through
the conduct of R&D in disease-endemic countries.
It is crucial that universities and other research institutions engage in
these international debates and developments. The increasing awareness
among researchers that millions are not reaping the benefits of medical
and scientific progress must be translated into concrete action and benefits
for those in greatest need.
18. John H. Barton, Preserving the Global Scientific and Technological Commons,
Address at the International Centre for Trade and Sustainable Development, U.N.
Conference on Trade and Development Policy Dialogue on a Proposal for an International
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